Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 2/20 | 0.49 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.45 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 7/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 7/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 7/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 7/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 7/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 7/20 | 0.41 |
| ▸ | GABRA4 | P48169 | 7/20 | 0.41 |
| ▸ | GABRA6 | Q16445 | 7/20 | 0.41 |
| ▸ | GABRP | O00591 | 6/20 | 0.41 |
| ▸ | GABRD | O14764 | 6/20 | 0.41 |
| ▸ | GABRB1 | P18505 | 6/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 6/20 | 0.41 |
| ▸ | GABRE | P78334 | 6/20 | 0.41 |
| ▸ | GABRG1 | Q8N1C3 | 6/20 | 0.41 |
| ▸ | GABRG3 | Q99928 | 6/20 | 0.41 |
| ▸ | GABRQ | Q9UN88 | 6/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1083587 | 0.85 | DGAT1 (0.55) | DGAT1USP30LPLLIPGHIF1A | |
| SCHEMBL30135556 | 0.85 | DGAT1 (0.55) | DGAT1USP30LPLLIPGHIF1A | |
| SCHEMBL1912346 | 0.81 | USP30 (0.56) | DGAT1USP30GABRA1GABRG2GABRB3 | |
| SCHEMBL30658717 | 0.81 | USP30 (0.56) | DGAT1USP30GABRA1GABRG2GABRB3 | |
| SCHEMBL16065191 | 0.80 | UCHL1 (0.42) | DGAT1UCHL1CYP1A2GABRA1GABRG2 | |
| SCHEMBL14054190 | 0.80 | USP30 (0.46) | DGAT1UCHL1USP30CYP1A2KDM4E | |
| SCHEMBL2799277 | 0.80 | DGAT1 (0.49) | DGAT1USP30CYP1A2LPLLIPG | |
| SCHEMBL2640279 | 0.80 | DGAT1 (0.49) | DGAT1USP30LPLLIPGALDH1A1 | |
| SCHEMBL18274843 | 0.79 | DGAT1 (0.47) | DGAT1UCHL1USP30LPLLIPG | |
| SCHEMBL8078534 | 0.79 | DGAT1 (0.50) | DGAT1UCHL1USP30LPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023122778-A1 | PYRIDAZINONE DERIVATIVES USEFUL AS T CELL ACTIVATORS | GOSSAMER BIO SERVICES, INC. (US) | 2023-06-29 | — | — | WO | disclosed |
| US-10759793-B2 | 2-(pyrazolopyridin-3-yl)pyrimidine derivatives as JAK inhibitors | ALMIRALL, S.A. (ES) | 2020-09-01 | — | — | US | disclosed |
| US-10280142-B2 | Bipyridyl compound | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2019-05-07 | — | — | US | disclosed |
| US-20190040063-A1 | TRICYCLIC COMPOUND FOR BROMODOMAIN-CONTAINING PROTEIN INHIBITOR AND PREPARATION PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2019-02-07 | — | — | US | disclosed |
| US-20190040063-A1 | TRICYCLIC COMPOUND FOR BROMODOMAIN-CONTAINING PROTEIN INHIBITOR AND PREPARATION PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2019-02-07 | — | — | US | disclosed |
| EP-3412669-A1 | TRICYCLIC COMPOUND FOR BROMODOMAIN-CONTAINING PROTEIN INHIBITOR AND PREPARATION, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF | Chia Tai Tianqing Pharmaceutical Group Co.,Ltd (CN) | 2018-12-12 | — | — | EP | disclosed |
| EP-3101004-B1 | BIPYRIDYL COMPOUND | JAPAN SCIENCE & TECH AGENCY (JP) | 2018-12-05 | — | — | EP | disclosed |
| EP-3096754-B1 | METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-08-29 | — | — | EP | disclosed |
| US-20180162856-A1 | 2-(PYRAZOLOPYRIDIN-3-YL)PYRIMIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2018-06-14 | — | — | US | disclosed |
| EP-3307272-A1 | 2-(PYRAZOLOPYRIDIN-3-YL)PYRIMIDINE DERIVATIVES AS JAK INHIBITORS | Almirall, S.A. (ES) | 2018-04-18 | — | — | EP | disclosed |
| WO-2017133681-A1 | TRICYCLIC COMPOUND FOR BROMODOMAIN-CONTAINING PROTEIN INHIBITOR AND PREPARATION, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF | 正大天晴药业集团股份有限公司 | 2017-08-10 | — | — | WO | disclosed |
| US-9708336-B2 | Metallo-beta-lactamase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-07-18 | — | — | US | disclosed |
| WO-2016198663-A1 | 2-(PYRAZOLOPYRIDIN-3-YL)PYRIMIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2016-12-15 | — | — | WO | disclosed |
| EP-3096754-A1 | METALLO-BETA-LACTAMASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2016-11-30 | — | — | EP | disclosed |
| US-20160333021-A1 | METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-11-17 | — | — | US | disclosed |
| US-20160251352-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2016-09-01 | — | — | US | disclosed |
| US-9371320-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-21 | — | — | US | disclosed |
| WO-2015112441-A1 | METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-07-30 | — | — | WO | disclosed |
| US-20150141406-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-21 | — | — | US | disclosed |
| EP-2857400-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2015-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160251352-A1 | HETEROCYCLIC COMPOUND | JAK2, JAK1, STAT3 | DGAT1 2448/4885UCHL1 3025/4885USP30 570/4885 |
| US-20180162856-A1 | 2-(PYRAZOLOPYRIDIN-3-YL)PYRIMIDINE DERIVATIVES AS JAK INHIBITORS | JAK2, JAK3, JAK1 | DGAT1 4366/4885UCHL1 4719/4885USP30 2460/4885 |
| US-10759793-B2 | 2-(pyrazolopyridin-3-yl)pyrimidine derivatives as JAK inhibitors | JAK2, JAK3, JAK1 | DGAT1 4366/4885UCHL1 4719/4885USP30 2460/4885 |
| US-20150141406-A1 | HETEROCYCLIC COMPOUND | JAK2, JAK1, STAT3 | DGAT1 2448/4885UCHL1 3025/4885USP30 570/4885 |
| US-20190040063-A1 | TRICYCLIC COMPOUND FOR BROMODOMAIN-CONTAINING PROTEIN INHIBITOR AND PREPARATION PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF | BRD3, BRD4, BRPF3 | DGAT1 2203/4885UCHL1 3516/4885USP30 1592/4885 |
| US-20160333021-A1 | METALLO-BETA-LACTAMASE INHIBITORS | MGAM, MGAM2, GAA | DGAT1 2534/4885UCHL1 216/4885USP30 2030/4885 |
| US-10280142-B2 | Bipyridyl compound | CBR1, NR0B2, ERBB2 | DGAT1 4357/4885UCHL1 4531/4885USP30 4159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.